The Biden administration proposed a rule to let Medicare and Medicaid cover obesity drugs like Ozempic. Millions would ...

The Federal Drug Administration (FDA) is warning consumers about unapproved semaglutide, a popular weight loss drug ...

The Biden administration is proposing a new rule to significantly expand the coverage of weight-loss drugs for Americans on ...

In clinical trials, most participants taking Wegovy or Mounjaro to treat obesity lost an average of 15% to 22% of their body ...

Here are six recent GLP-1 studies: 1. The use of Ozempic and Wegovy reduced healthcare costs for overweight or obese patients with heart failure or atherosclerotic cardiovascular disease, according to ...

Should employers, patients or insurers cover the $411 billion annual cost for GLP-1 drugs? U.S. healthcare industry grapples with this question as demand grows.

Before he leaves office, President Joe Biden is proposing a last-minute item with some bipartisan support that could be very ...

Millions of obese Americans would be eligible to have popular weight-loss drugs like Wegovy or Ozempic covered by Medicare or ...

The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden ...

If the proposal is finalized, it could set the stage for a showdown between the pharmaceutical industry and the Trump ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss medications received by RFK Jr.

President Biden's proposal for Medicaid and Medicare coverage for weight loss drugs such as Ozempic and Wegovy could draw ...